# PHASE 5D STATUS — FINAL DATA CONSOLIDATION

**Project:** Drug Interaction Analysis Using Pharmacokinetic Trajectories and Drug–Target Networks  
**Phase:** Phase 5D — Final Data Consolidation  
**Date:** 2026-10-08  
**Status:** COMPLETE & SCIENTIFICALLY VALIDATED (`PHASE 5D STATUS = PASS`)  

---

## 1. Objective
Consolidate all validated outputs from Phases 1 through 5C.3 into definitive master datasets and summary tables. This phase serves as the final research-pipeline step, freezing the dataset and preparing all deliverables without altering the underlying methodology or prior scientific findings.

## 2. Final Cohort
- **Final Validated Drugs ($N=7$):** cefamandole, indomethacin, phenobarbital, quinidine, remifentanil, theophylline, xanomeline
- **Canonical Ordering:** Strictly preserved across all master files.
- **Human Subjects:** 452
- **Valid PK Observations:** 5,174
- **Excluded PK Data:** 43 initial candidates rejected due to a lack of continuous $C(t)$ data. No rejected data was reintroduced.

## 3. Validated Methods
- **PK Preprocessing:** Dose normalization (per mg) and Peak normalization ($C_{\max} = 1.0$) across a 15-point standardized time grid ($0 - 24$ hours).
- **Trajectory Decomposition:** Low-rank SVD ($r=2$) preserving $\ge 93\%$ cumulative variance, alongside discrete Dynamic Mode Decomposition (DMD).
- **Target Network Analysis:** ChEMBL bipartite mapping capturing 196 unique targets and 222 interaction edges, quantified via Jaccard and Cosine similarity.
- **Analytical Coupling:** Non-parametric Mantel matrix permutation tests ($10,000$ permutations).

## 4. Key Numerical Results
- **SVD Variance Captured:** Rank 2 component captures at least $93.8\%$ of the dataset variance for peak-normalized trajectories.
- **Total Interaction Edges:** 222 (Density = 0.1618)
- **Mantel Permutation Count:** 10,000

## 5. Clustering Findings
- Hierarchical (Ward/Average) and k-Means clustering on SVD and DTW distances effectively partitioned the 7-drug cohort into distinct kinetic morphologies (rapid IV clearance vs. extended oral elimination).
- These partitions are rigorously kinetic and are **not** treated as biological proof of interaction.

## 6. PK-Target Coupling Findings
- **Coupling Status:** `EXPLORATORY_WEAK` (or non-significant).
- **Mantel p-values:** Ranged from $p = 0.3053$ to $p = 0.7678$. 
- **Scientific Conclusion:** There is no statistically significant linear or monotonic coupling between macroscopic PK trajectory distance and primary ChEMBL drug–target profile distance.

## 7. Limitations
- **Small Pilot Cohort:** Limited to $N=7$ highly diverse therapeutics.
- **Heterogeneous Routes:** Mixing IV and Oral routes introduces absorption delays that impact macroscopic similarities.
- **Subject-to-Drug Aggregation:** Granular inter-patient variances are collapsed into mean trajectory models.
- **Mantel Sensitivity:** The network yields only 21 unique pairwise comparisons; low power makes non-significant findings mathematically expected for non-congeneric drugs.

## 8. Reproducibility
- No subject-level pseudo-replication exists in the consolidated data.
- The random seed for the Mantel permutation test was fixed at 42.
- The entire process is strictly reproducible using the canonical outputs from prior phases.

## 9. Generated Files (`data/processed/final/`)
- `final_cohort_summary.csv`
- `final_svd_dmd_results.csv`
- `final_pk_similarity_summary.csv`
- `final_target_network_summary.csv`
- `final_clustering_summary.csv`
- `final_pk_target_coupling_summary.csv`
- `final_integrated_results.csv`
- `PHASE_5D_STATUS.md`

*(Accompanying consolidated figures are located in `outputs/figures/final/`)*

## 10. Test Results & Final Status
- **Total Tests:** 73
- **Passed:** 71
- **Skipped:** 2
- **Failed:** 0
- **Final Status:** The scientific research pipeline is fully complete and the dataset is definitively frozen.
